(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acid

10/01/2019 - "A selective PPARα modulator, Pemafibrate, effectively improved hypertriglyceridemia without major adverse events in real practice, with half dose once-daily administration. "
07/15/2021 - "Conclusion Pemafibrate treatment may be safe and effective for MAFLD patients with hypertriglyceridemia."
10/01/2023 - "Pemafibrate improved diastolic function in patients with T2D and hypertriglyceridemia, suggesting that PPARα activation by pemafibrate prevents the development of DCM at an early stage."
10/01/2019 - "Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice."
07/01/2023 - "The aims of this study were to evaluate the efficacy and safety of pemafibrate in hypertriglyceridemia patients under clinical settings. "

09/29/2023 - "Conclusion Pemafibrate is effective in ALT normalization in patients with NAFLD and may be used as a treatment for NAFLD."
06/01/2023 - "Longer-term treatment may be necessary to influence VATI and thus to further evaluate the relationship between improved body composition and NAFLD with pemafibrate treatment."
12/09/2021 - "We retrospectively evaluated the efficacy of pemafibrate in 16 NAFLD patients (11 men and 5 women; median age, 59 years; range, 27-81 years) who had taken pemafibrate for at least one year. "
12/01/2020 - "The aim of this single-arm prospective study is to evaluate the efficacy of pemafibrate in NAFLD patients with DL. "
08/01/2020 - "We retrospectively evaluated the efficacy of pemafibrate in patients with NAFLD. "

06/01/2023 - "Pemafibrate improved dyslipidemia, liver function, and hepatic reserve. "
02/08/2022 - "Here, we aimed to study the effects of the novel selective PPARα modulator, pemafibrate, on metabolic parameters in patients with dyslipidemia. "
01/01/2018 - "In a previous phase 2 trial, we showed excellent efficacy and safety of pemafibrate in patients with dyslipidemia. "
07/21/2023 - "Pemafibrate used in clinical practice for dyslipidemia was developed as a selective PPARα modulator (SPPARMα). "
11/13/2019 - "Pemafibrate is predicted to exhibit beneficial effects in patients with atherogenic dyslipidemia and diabetic microvascular complications."

01/01/2017 - "In a phase-2 study, pemafibrate was shown to improve liver dysfunction in patients with dyslipidaemia. "
10/26/2023 - "The hepatoprotective effects of pemafibrate were dominant in subjects with type 2 diabetes complicated with liver dysfunction. "
03/01/2023 - "Switching to pemafibrate could improve adverse effects due to bezafibrate, and appeared effective against liver dysfunction in cholestatic liver disease patients with incomplete response to bezafibrate."
03/01/2023 - "The present study aimed to evaluate the safety and efficacy of switching from bezafibrate to pemafibrate in patients with chronic liver disease. "
03/01/2023 - "Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease."

01/01/2020 - "A large-scale trial of pemafibrate, PROMINENT, for dyslipidemic patients with type 2 diabetes is ongoing. "
05/01/2019 - "A large-scale trial PROMINENT using pemafibrate for patients with type 2 diabetes is in progress. "
01/01/2019 - "The aim of this study was to evaluate the efficacy and safety of pemafibrate in people with type 2 diabetes and hypertriglyceridaemia over a 52-week period. "
10/01/2023 - "We thus investigated the effects of pemafibrate on cardiac diastolic function in patients with type 2 diabetes. "
10/01/2023 - "Effects of pemafibrate on left ventricular diastolic function in patients with type 2 diabetes mellitus: a pilot study."